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Abstract: Bottromycin A2 is a structurally unique ribosomally
synthesized and post-translationally modified peptide (RiPP)
that possesses potent antibacterial activity towards multidrug-
resistant bacteria. The structural novelty of bottromycin stems
from its unprecedented macrocyclic amidine and rare b-
methylated amino acid residues. The N-terminus of a precursor
peptide (BtmD) is converted into bottromycin A2 by tailoring
enzymes encoded in the btm gene cluster. However, little was
known about key transformations in this pathway, including
the unprecedented macrocyclization. To understand the path-
way in detail, an untargeted metabolomic approach that
harnesses mass spectral networking was used to assess the
metabolomes of a series of pathway mutants. This analysis has
yielded key information on the function of a variety of
previously uncharacterized biosynthetic enzymes, including
a YcaO domain protein and a partner protein that together
catalyze the macrocyclization.
Ribosomally synthesized and post-translationally modified
peptides (RiPPs) are natural products that are prevalent
throughout nature,[1] and their biosynthetic pathways are
capable of transforming simple proteinogenic amino acids
into structurally complex compounds that have potent
bioactivities.[2–4] However, elucidating the biosynthesis of
RiPPs can be hindered by the difficulty of isolating inter-
mediates, as the biosynthesis takes place on a larger precursor
peptide, and intermediates may be rapidly proteolyzed.
Therefore, improved methods for the identification of RiPP
intermediates are desirable. Bottromycin A2 (1, Scheme 1)
[5–8]
possesses potent antibacterial activity towards multidrug-
resistant bacteria,[9] and is structurally unique owing its
unprecedented macrocyclic amidine, rare b-methylated
amino acids residues, and a terminal thiazole. Nature employs
a variety of strategies for peptide macrocyclization,[10–12] but
amidine formation has only been observed for bottromycin.
Initial studies on bottromycin biosynthesis showed that its
amino acids were b-methylated by radical SAM methyltrans-
ferases[5,7] (RSMTs), but the rest of the bottromycin pathway
represented a biosynthetic black box, where little was known
about key steps in the pathway, including the unprecedented
macrocyclization. In this study, we employ untargeted metab-
olomics and mass spectral networking to deduce the biosyn-
thetic route to bottromycins in Streptomyces scabies. This
analysis identifies the enzymes responsible for macrocycliza-
tion, thiazole formation, and aspartate epimerization, thereby
demonstrating the utility of an untargeted metabolomic
approach for elucidating a targeted biosynthetic pathway.
To assess the role of the putative tailoring genes in the
bottromycin pathway (Supporting Information, Figure S1),
we had previously generated S. scabies DbtmC, DbtmE,
DbtmF, DbtmI, and DbtmJ, but were unable to identify
bottromycin-like compounds in these mutants.[5] We therefore
established that these deletions did not lead to deleterious
polar effects on the pathway by successfully complementing
each mutant strain with a copy of the deleted gene (Support-
ing Information, Table S2 and Figure S2). Furthermore, an
RT-PCR analysis of wild-type and DbtmD strains showed that
transcription still occurs in the absence of the precursor
peptide at a comparable level to the wild-type (WT) strain
(Supporting Information, Figure S3), indicating that there is
no essential regulatory feedback mechanism associated with
the production of a pathway intermediate.[13]
Therefore, a comparative untargeted metabolomic anal-
ysis was carried out using WT S. scabies alongside the DbtmC,
DbtmD, DbtmE, DbtmF, DbtmG, DbtmI, and DbtmJ deletion
strains. Untargeted metabolomics is frequently used to assess
the total metabolome of an organism,[14] for example to
prioritize strains and compounds for drug discovery,[15,16] or to
identify novel natural products,[17] but has rarely been used to
assess a single pathway. High-resolution liquid chromatog-
Scheme 1. Conversion of BtmD into bottromycin A2 (1).
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raphy–mass spectrometry (LC-MS) data for triplicate three-
day production cultures of each strain (Supporting Informa-
tion, Figure S4) were analyzed using two untargeted compa-
rative metabolic methods. First, global LC-MS metabolomic
profiles for each strain were used to generate an aligned data
matrix that indicated significant differences between each
mutant (Supporting Information, Table S5). This dataset was
filtered to remove any metabolites that appeared in either
DbtmD or the production medium. Mature bottromycins (1–
5, Figure 2) were clearly absent in every mutant, but the
complexity of the data hampered the detailed character-
ization of metabolites. Therefore, this was followed by mass
spectral network analysis,[18] which is a powerful tool that
identifies similarities in MS2 fragmentation data and builds
a network of species with relatedMS2 spectra, thus identifying
structurally-related molecules within a complex mixture.[18–24]
This has been used to assess the global metabolic profiles of
a single organism, either in isolation[19] or when interacting
with neighboring species,[18] to compare the metabolomes of
related organisms,[20–22] to assess the metabolic potential of
a new bacterial taxon,[23] and to identify metabolites related to
the colibactin pathway.[24]
Mass spectral network analysis of WT, DbtmC, DbtmD,
DbtmF, DbtmI, and DbtmJ strains revealed an extensive
metabolic network (Supporting Information, Figure S5). An
analysis of the metabolomes of DbtmE and DbtmG was used
to map molecules produced by these mutants onto this
network. Nodes representing species that were not present in
DbtmD were manually assessed using MS2 to identify
molecules related to the btm pathway. This global metabolo-
mic analysis showed that the bottromycin pathway contrib-
utes much more to the total metabolite profile of S. scabies
than was previously understood,[25] and identified 14 distinct
molecules in the wild-type strain, and at least 6 additional
molecules across the mutant strains, with masses and frag-
mentation patterns that are entirely consistent with bottro-
mycin-like molecules (1–20 ; Figure 1, Figure 2; Supporting
Information, Figures S6–S23, Table S3). The only significant
molecule that was not revealed by network analysis, owing to
a lack of MS2 fragmentation homology, was an abundant
species with m/z 406.27 (17; Figure 2; Supporting Informa-
tion, Figure S17), which was identified by the initial compa-
rative analysis of LC-MS data. The abundance of various
bottromycin-like metabolites in WT S. scabies (Figures 1;
Supporting Information, Figure S23) indicates that there are
significant bottlenecks in the biosynthetic pathway that
preclude the efficient processing of BtmD into bottromycin.
Instead, partially processed BtmD can be proteolyzed, and
the data show that there are multiple points at which the
pathway stalls. The diversity of bottromycin-like molecules
produced by theWT could explain why it was difficult in prior
studies to identify novel metabolites from mutants.
The macrocyclic amidine of bottromycin is unique in
nature, and a plausible biosynthetic route involves the
nucleophilic attack of Gly1 onto the amide bond between
Val4 and Val5, which could require the activation of the
amide carbonyl. YcaO domain proteins activate backbone
amide bonds by phosphorylation[26,27] or adenylation[28] of the
carbonyl oxygen, and all YcaO domain proteins with
a characterized activity have a partner cyclodehydratase
that aids catalysis of cyclization to oxazolines or thiazolines.[29]
The bottromycin gene cluster encodes two YcaO domain
proteins, BtmE and BtmF, but no cyclodehydratases. There-
fore, we hypothesized that one participates in macrocycliza-
tion and the other is involved in the formation of the terminal
thiazole.
Analysis of the comparative metabolomic and MS2 net-
work datasets revealed two newmolecules (m/z 873.45 andm/
z 887.47) produced by both DbtmF and the amidohydrolase
mutant DbtmI, but not by WT S. scabies. Masses of 873.45 Da
and 887.47 Da correspond to the addition of H2O to
carboxylated O-desmethylated bottromycins A2 (1) and
C2,
[25] respectively, which indicated that one of the cyclo-
dehydrations does not occur in DbtmF and DbtmI. MSn
revealed that these molecules are not macrocyclized but do
feature the thiazoline ring (10 and 11; Figure 3a; Supporting
Information, Figure S10), thus indicating that BtmFand BtmI
cooperate to catalyze amidine ring formation, but are not
required for thiazoline formation. Both mutant strains also
produced a range of other bottromycin derivatives that
contain a thiazoline ring but no macrocycle (Figure 1,
Figure 2; Supporting Information, Figure S23). DbtmI did
produce trace amounts of macrocyclized 7 and 13, which
could reflect inefficient spontaneous cyclization following
BtmF-catalyzed amide activation. A cyclization mechanism is
proposed (Figure 3b) where BtmF activates the amide bond
Figure 1. Bottromycin mass spectral network from WT S. scabies and
a series of pathway mutants. Each node represents one metabolite and
edge thickness between nodes reflects the relative similarity of MS2
data. The WT network is annotated with all observed m/z data and is
enlarged 2 for clarity. Gray nodes indicate an absence of a compound
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using ATP and BtmI catalyzes cyclization. Further experi-
ments with purified proteins will be needed to verify this,
especially in relation to timing of ATP activation. Cyclization
is contingent on the removal of the N-terminal methionine,
which is usually catalyzed by endogenous aminopeptidases,
but these do not function efficiently with an MGP
sequence.[30] In vitro analysis of the M17 peptidase[31] BtmM
with BtmD demonstrated that BtmM catalyzes this reaction
when either Zn2+ or Co2+ are used as co-factors (Supporting
Information, Figures S25 and S26).
In contrast toDbtmF, the only abundant species that could
be confidently assigned as a BtmD-derived metabolite in
DbtmE was 17 (Supporting Information, Figure S16), which is
a trimethylated tripeptide that is also found in the WT,
DbtmF, DbtmI, and DbtmJ strains (Supporting Information,
Figure S23). This assignment is consistent with the absence of
17 in DbtmD and in the RSMT mutants DbtmC and DbtmG.
Unfortunately, this provided no evidence on Cys8 cyclization;
the absence of cysteine-containing peptides could reflect
rapid peptide degradation when cyclization does not occur.
The lack of any thiazole or thiazoline-containing metabolites
does imply that BtmE catalyzes thiazoline formation,
although further in vitro characterization is required to
confirm this. The absence of macrocyclized metabolites
suggests that thiazoline formation is an early step in the
pathway. BtmH, the only uncharacterized hydrolytic enzyme
in the pathway, is proposed to remove the follower peptide,
although it is possible that it could also participate in
heterocyclization.
The btm cluster lacks a flavin-dependent dehydrogenase
that is required for the biosynthesis of all other thiazole/
oxazole-containing RiPPs.[29] Instead, a P450 enzyme, BtmJ,
was predicted to catalyze the oxidative decarboxylation of the
thiazoline into a thiazole.[5–7] This is an uncommon role for
a P450, although it has been reported for thiazole formation
in the biosynthesis of the plant alkaloid camalexin[32] and
could be mechanistically similar to the fatty acid P450
decarboxylase OleT.[33] Analysis of DbtmJ revealed two
abundant compounds with m/z 841.43 and 855.44 (Figure 4),
which were confirmed to be carboxylated O-desmethyl
bottromycins B2 and A2, respectively (12 and 13) using MS
2
(Supporting Information, Figure S11).
Interestingly, two distinct peaks are observed by LC-MS
for both m/z 855.44 and 841.43 (Figure 4a), and each pair of
Figure 2. Bottromycin pathway metabolites identified in this study.
Predicted stereochemistry is based on the ribosomal origin of each
amino acid, although Asp7 stereochemistry is not provided for some
compounds owing to the potential for epimerization and correspond-
ing double peaks in their LC traces.
Figure 3. Macrocyclization catalyzed by BtmF and BtmI. a) Character-
ization of 10 and 11 produced by S. scabies DbtmF and DbtmI. Further
MS2 and MS3 characterization is shown in the Supporting Information,
Figure S10. b) Proposed macrocyclization mechanism.
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peaks with the same mass have identical MS2 fragmentation
patterns (Supporting Information, Figure S11). This could
reflect a mixture of epimers at the aspartate residue, which
has a non-proteinogenic d-stereocenter in bottromycin A2.
Therefore, we hypothesized that aspartate epimerization
occurs after thiazoline formation, when the pKa of the
aspartate a-proton is lowest owing to imine–enamine tauto-
merization that is disfavored once the aromatic thiazole is
formed (Figure 4b). This is consistent with previous reports of
epimerization of amino acids adjacent to carboxylated thiazo-
lines,[34] and we could observe spontaneous interconversion of
these peaks at pH 7.5 (Supporting Information, Figure S12).
To further assess whether this proton is exchangeable, we
carried out a deuterium labeling experiment. Here, all
exchangeable protons were replaced with deuterium in
D2O, the thiazoline was then hydrolyzed back to Cys in
dilute aq. DCl, and the sample was finally treated with H2O.
Theoretically, this would trap a deuterium in the Asp a-
position as back exchange would be prevented following loss
of the thiazoline. This indeed showed specific incorporation of
one deuterium into 13 at Asp7 (Supporting Information,
Figures S13 and S14), indicating that this position can readily
undergo non-enzymic epimerization. The drop in abundance
of both forms of m/z 855.44 in the WT compared to DbtmJ
(Supporting Information, Figure S23) implies that a dynamic
kinetic resolution converts this mixture of epimers into
stereochemically pure mature bottromycins.
To investigate whether any of the metabolites reported
are authentic pathway intermediates, each mutant strain was
co-cultivated with DbtmD, which is unable to produce the
precursor peptide. Any diffusible molecules produced by
mutants that are genuine intermediates should be converted
into 1 by the functional enzymes in DbtmD. Only theDbtmJ+
DbtmD co-cultivation resulted in the production of 1 (Sup-
porting Information, Figure S27), which implies that 12 and
13 are true intermediates and supports the proposed roles and
substrate specificities of BtmJ and BtmB. In contrast, the
failure of the DbtmF and DbtmI co-cultivation experiments
suggests that the linear compounds 10 and 11 are shunt
metabolites rather than authentic intermediates, and that
BtmF and BtmI require a substrate that contains a follower
peptide. However, we cannot rule out the possibility that 10/
11 are not exported/imported as effectively as 12/13. The lack
of an O-methyl group on the d-aspartyl residue in any of the
metabolites identified from mutant strains indicates that O-
methylation is the last step in the pathway, thereby generating
an active antibiotic.[35] This was supported by the in vitro O-
methylation of 4 using recombinant BtmB (Supporting
Information, Figure S28).
Three RSMTs catalyze four C-methylations in the btm
pathway.[5,7] In S. scabies, bottromycin production is either
severely reduced or entirely abolished when either RSMT
gene, btmC or btmG, is deleted. BtmG methylates Val4 and
Val5, and BtmC methylates Phe6,[5,7] but it is unclear why the
pathway stalls when either step is missed. The metabolic
datasets showed that both DbtmC and DbtmG have highly
similar metabolite profiles, and the production of macro-
cyclized shunt metabolites 6 and 7 indicates that C-methyl-
ation is not a prerequisite for cyclization. However, the fully
C-methylated metabolites produced by DbtmF and DbtmI
demonstrate that macrocyclization is not a prerequisite for C-
methylation either. Also, the production of methylated
tripeptides by DbtmC and DbtmG indicates that the pathway
can stall before cyclization when C-methylation is disrupted.
The data are consistent with incomplete C-methylation
reducing the efficiency of various downstream modification
steps.
There has been widespread recent interest in both the
biosynthesis[5–8] and biological activity[9,35] of bottromycin
owing to its unusual structure and potent antimicrobial
activity. In this study, we have harnessed untargeted metab-
olomics to elucidate the biosynthetic pathway to bottromycin
Figure 4. BtmJ-catalyzed oxidative decarboxylation. a) LC-MS spectra
showing double peaks for 12 and 13 identified in S. scabies DbtmJ.
b) Mechanistic proposal for epimerization followed by oxidation.
Scheme 2. Revised bottromycin pathway.
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A2 (Scheme 2; Supporting Information, Table S4). Our anal-
ysis identified a wide array of metabolites related to
bottromycin, and the untargeted metabolomic data matrix
(Supporting Information, Table S5) indicates that there may
be further, currently uncharacterized, metabolites produced
by this pathway. This study also reveals the first example of
YcaO domain-catalyzedmacrocyclization, which provides the
foundation for detailed mechanistic investigations into this
step.
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A detailed understanding of bottromycin
biosynthesis was obtained by harnessing
a mass-spectral network (represented by
colored nodes in the picture) to analyze
a series of pathway mutants. This method
provides fresh insights into how this
potent antibiotic is assembled, and
shows that a YcaO domain protein works
with a hydrolase-like protein to catalyze
the formation of the macrocyclic amidine.
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